# Axon Enterprise (AXON) — InvestMoat Analysis

_Last analyzed: August 6, 2026_
_Asset class: equity · Canonical page: https://investmoat.com/stocks/axon_

## Scores

| Dimension | Score (0–100) |
| --- | --- |
| Moat durability | 92 |
| Growth trajectory | 93 |
| Valuation | 74 |
| **Composite** | **89** |
| **Recommendation** | **Strong Buy** |

Scores are computed deterministically from this asset’s data by the InvestMoat formula (see https://investmoat.com/llms.txt for methodology). Scores are not directly comparable across asset classes.

## Key stats

- **Ticker:** AXON
- **Market Cap:** ~$42B

## Moat

Axon controls ~85% of major U.S. law enforcement body camera contracts, owns the only evidence management platform (Evidence.com) legally accepted in court at scale, and has $15.1B in contracted backlog (+41% YoY in Q2 2026) — the strongest regulatory and system-of-record moat in public safety technology. Dedrone counter-drone just cleared $100M quarterly revenue and Axon landed its first full-scope Axon 911 customer, extending the bundle from evidence capture into airspace security and emergency dispatch.

### The Public Safety Operating System Moat

Axon's moat is built on three interlocking and self-reinforcing pillars: **Regulatory Lock-in, System of Record, and Proprietary Training Data**:

- **Evidence.com — The Legal System of Record:** Evidence.com is the chain-of-custody platform for digital evidence submitted to courts across thousands of U.S. jurisdictions. Law enforcement agencies cannot switch evidence management providers mid-contract without potentially invalidating evidence admissibility — a legal risk that creates the highest-stakes switching costs in any software vertical. Multi-year contracts of 7–10 years, combined with $15.1B in contracted future bookings (+41% YoY), mean that Axon's revenue runway is visible through most of the current decade. More than one-third of software revenue now comes from offerings beyond core evidence management (Fusus real-time ops, Records, AI Era Plan, counter-drone software, Axon 911), which grew ~70% YoY in Q2 2026.
- **Draft One — AI Moat Built on Irreplaceable Data:** Draft One uses generative AI trained on body-camera footage and police report data that Axon uniquely possesses. With ~85% market share in major U.S. cities, Axon holds a training data advantage that no competitor can replicate — you cannot build a police report AI without access to police body camera footage at scale. In Q2 2026, AI Era Plan revenue again grew nearly 700% YoY, and three of Axon's five largest AI Era Plan deals in the quarter were international — validating both willingness to pay for AI as a discrete OSP tier and geographic expansion of the attach story.
- **Bundled Platform — From TASER to Dedrone to 911:** Axon has extended its platform from TASER + Body Camera + Cloud Evidence to now include Dedrone counter-drone (>$100M quarterly revenue in Q2 2026; named in a $1.5B DHS C-UAS program), Drone First Responder, AI dispatch (first full-scope Axon 911 customer via Prepared/Carbyne), Draft One AI reports, and commercial body cameras (Axon Body Mini in enterprise trials). Agencies that adopt the full Officer Safety Plan (OSP) bundle are locked in for a decade across hardware, software, and AI layers simultaneously — a bundle that point-solution competitors building only one component of the stack cannot compete against.

**Moat verdict:** Axon remains a strong net beneficiary of AI — Draft One makes the platform more valuable per officer, deepens the software ARR attach rate (ARR re-accelerated to +39% in Q2), and creates a data flywheel built on body camera footage that competitors cannot access. The key AI-resilient moats are proprietary data, regulatory lock-in, and system of record — all three are strengthened, not threatened, by the AI era. Q2 also showed the bundle extending into airspace (Dedrone >$100M) and dispatch (first full-scope Axon 911), which deepens switching costs without changing any moat status. The primary AI risk is commoditisation of police report-writing tools if body camera data becomes more accessible; contractual data exclusivity makes that unlikely inside a five-year horizon. Watch software gross-margin mix (71.3% in Q2, −430 bps YoY) as the tell on whether newer AI and platform products dilute or eventually expand unit economics.

## Growth

Q2 2026 delivered $904M revenue (+35% YoY), beating consensus by ~$28M and marking the 10th consecutive quarter of 30%+ growth. ARR re-accelerated to $1.64B (+39% YoY) with net revenue retention at 126%, future contracted bookings grew 41% to $15.1B, and AI Era Plan revenue again surged nearly 700% YoY. Platform Solutions jumped 123% to $150M as Dedrone cleared $100M quarterly revenue; international and enterprise bookings each roughly tripled YoY, and Axon signed its first full-scope Axon 911 customer plus two nine-figure city agreements (including its largest individual TASER order). Management raised FY2026 revenue growth guidance a second time, to 32–34% (from 30–32%), and maintained the ~25.5% Adjusted EBITDA margin outlook. The written Outlook no longer carries formal OCF/FCF lines — CapEx is guided at $160–190M — though on the call management said it still has line of sight to the prior ~$450M FY26 FCF figure, back-half weighted. Implied H2 growth at the guide midpoint (~32%) is a modest step-down from Q2's 35%; the regular-session selloff keyed more on software GM compression and the missing formal cash-flow guide than on the top-line raise.

- **Revenue CAGR estimate:** 29–33%
- **Primary type:** both
- **Margin trend:** expanding
- **Key risk (moderate):** If U.S. federal DOJ grant funding is cut 15%+ and 20%+ of agencies delay new OSP signings into 2027, or if Dedrone's World Cup / DHS pipeline proves event-driven rather than a durable product line, bookings growth decelerates below 25% and the $6B 2028 target needs commercial penetration not yet proven at scale — partially offset by Q2's ~3× international and enterprise bookings, ARR re-acceleration to +39%, and the $15.1B backlog (~4.1× FY26 sales). Three live secondary risks: (1) political/procurement scrutiny around federal immigration-enforcement awards and a disclosed presidential stock purchase that could complicate no-bid deals; (2) software & services gross margin compressed 430 bps YoY to 71.3% on newer-product mix (software-only still >80%), with tariff refunds flattering Q2 and memory/component costs flagged as a H2 headwind; (3) the written FY26 Outlook dropped formal OCF/FCF guidance even as the call kept oral line-of-sight to ~$450M FCF, and SBC remains $590–620M (~16–17% of guided sales) — so GAAP profitability and cash conversion can lag the EBITDA print even when revenue beats.
- **Drivers:**
  - Software & Services (ARR) — Q2 2026 software & services revenue $398M (+36% YoY); ARR $1.64B (+39%, re-accelerating from Q1's +35%); NRR 126% (accelerating)
  - AI Era Plan & Draft One — AI Era Plan revenue nearly +700% YoY in Q2 2026; three of five largest AI Era deals were international; still the primary new ACV attach driver inside OSP (accelerating)
  - Platform, Dedrone & International — Platform Solutions $150M (+123% YoY); Dedrone >$100M quarterly; connected devices $507M (+35%); international and enterprise bookings each ~3× YoY; first full-scope Axon 911 customer (accelerating)
- **Score derivation:** Base 90 (29–33% blended CAGR midpoint 31%) + 4 trajectory (all three drivers accelerating: ARR re-accelerated to +39%, AI Era ~+700%, Platform/Dedrone +123%) + 4 margin (Adjusted EBITDA margin 26.8% in Q2 vs 25.5% FY guide; connected-devices GM +330 bps YoY) − 5 moderate residual risk (federal/political procurement scrutiny and software GM compression to 71.3%) = 93. Kept the CAGR band: a second consecutive intra-year guide raise is charged in the drivers and in the guide itself, not by rebasing the multi-year slope on one print.

## Valuation

AXON closed Aug 6 at $522 (~$42B) — down ~14% on the day and ~14% from the $609 Aug 5 close into the print — after beating revenue/EPS/EBITDA and raising FY26 growth guidance to 32–34%. The regular session sold through the ~$570 after-hours print as the market keyed on software GM compression (−430 bps YoY to 71.3%) and the written Outlook omitting formal OCF/FCF lines (call still said line of sight to ~$450M FCF). At $522 the stock sits ~16% below our $620 base and ~41% below the August 2025 ATH of ~$886. On the raised ~$3.70B FY26 revenue midpoint it trades ~11.4× NTM P/S and ~58× forward non-GAAP P/E (~$9.00 consensus) — PEG ~1.8×, cleanly under the 2.0× line the July ICE-spike print had breached. With bear $340 (~35% downside), base $620 (~19% upside), and bull $850 (~63% upside), the post-print tape restores a clearer margin of safety than either the ~$622 ICE spike or the overnight ~$570 print: the Q2 beat, second guide raise, ARR re-acceleration, and Dedrone scale-up still justify the raised ladder, and the session wipeout pays you more for the same fundamentals.

| Multiple | Value | Note |
| --- | --- | --- |
| Trailing P/E (GAAP) | ~225× | GAAP heavily distorted by stock-based comp (~$144M in Q2; FY26 SBC guide $590–620M) |
| Forward P/E (NTM, non-GAAP) | ~58× | ~$9.00 consensus non-GAAP EPS at the $522 Aug 6 close (~63× at the overnight ~$570 print; ~68× at the $609 pre-print close) |
| PEG Ratio | ~1.8× | fwd P/E ÷ ~33% revenue/EPS growth band — further under the 2.0× 'expensive' threshold |
| Price / Sales (NTM) | ~11.4× | ~$3.70B NTM revenue (raised 2026 guide midpoint of 32–34% on $2.78B FY25) |
| Price / FCF | ~94× | oral line-of-sight to FY26 FCF ~$450M (not in written Outlook); Q2 FCF −$1M on inventory build, back-half weighted |

At the $522 Aug 6 close AXON trades ~11.4× NTM P/S and ~58× forward non-GAAP P/E with PEG ~1.8× — cheaper than the overnight ~$570 / ~12.4× / ~63× / ~1.9× PEG print and well below the ~$622 / ~13.7× / ~79× / ~2.5× PEG setup in early July. The $15.1B backlog (+41% YoY), second FY26 guide raise to 32–34%, ARR re-acceleration to +39%, and Dedrone clearing $100M quarterly still support the raised scenario ladder of $340 / $620 / $850. Against that triangulation the session wipeout offers ~19% upside to base and ~63% to bull versus ~35% downside to bear — a constructive asymmetry, provided software GM compression, the missing formal cash-flow guide, and SBC intensity do not keep GAAP/FCF conversion from validating the EBITDA story. _(as of August 6, 2026)_

## Price scenarios

### Bear — $340

Federal DOJ grant cuts and political/procurement scrutiny slow new OSP signings, Dedrone demand normalises after World Cup/DHS headlines, software gross-margin mix stays compressed, and Draft One faces regulatory backlash — 2026 revenue misses the low end of the raised guide, re-rating the multiple to ~8× NTM revenue.

- DOJ federal grant cuts of 15%+ cause 25%+ of agencies to defer new OSP renewals into 2027–28, Dedrone's >$100M quarterly run-rate proves event-driven rather than a durable product line, and five-year normalized bookings decelerate below 20% — consensus 2026 revenue comes down by $300M+ toward ~$3.4B
- FTC or DOJ antitrust action targets the Prepared/Carbyne acquisitions or the DHS C-UAS participation, stalling Axon 911 and counter-drone TAM expansion
- A high-profile wrongful arrest linked to a Draft One AI-generated report triggers congressional hearings, a federal moratorium on AI-generated police reports, and software ARR growth slows below 20%
- Multiple compresses to ~8× NTM P/S on reduced ~$3.4B revenue (≈$27B mkt cap / ~$340), as growth expectations reset and the regulatory/political risk discount widens

### Base — $620

Axon delivers the raised 2026 guide of 32–34% revenue growth (~$3.70B midpoint), ARR crosses $1.9B, Dedrone sustains as a >$100M quarterly product line, and the $15.1B backlog converts on plan — multiple holds ~12× on end-2026 NTM revenue (~$4.2B into 2027) as international/AI/counter-drone diversification de-risks the path to the $6B 2028 target.

- FY2026 revenue lands at $3.65–3.75B, mid-to-high end of raised guidance, with large agency renewals, AI Era Plan upsells, and Dedrone continuity driving ARR to $1.90–2.00B by Q4 2026
- Adjusted EBITDA margin holds the ~25.5% guide (Q2 printed 26.8%) and FY26 FCF lands at or above the ~$450M oral line-of-sight as inventory investment moderates in H2
- Dedrone annualises as a durable product line beyond World Cup deployments, with meaningful contribution from the DHS $1.5B C-UAS program and international/enterprise airspace-security demand
- International and enterprise continue to compound off Q2's ~3× bookings pace, and Axon 911 converts the first full-scope customer into a referenceable pipeline of dual Prepared+Carbyne wins
- Multiple holds ~12× on end-of-2026 NTM revenue (~$4.2B rolling into 2027) as $15.1B backlog conversion and ARR durability validate the $6B 2028 trajectory — fair value near ~$620, below street's pre-revision ~$690 average target

### Bull — $850

Draft One becomes a default OSP attach, Dedrone wins a material share of federal/international C-UAS spend, and Axon 911 scales from the first full-scope win into hundreds of dispatch centers — revenue trajectory re-rates toward the $6B 2028 target ahead of schedule and the multiple expands back toward prior-cycle highs.

- Draft One / AI Era Plan penetrates 80%+ of the installed base by end of 2026, pushing total ARR toward $2.2B+ and sustaining ARR growth in the mid-40%s — the swing factor of the bull case, not a foregone conclusion
- Dedrone plus Axon Body Mini commercial/enterprise wins add a third revenue pillar beyond traditional law enforcement, with Dedrone capturing a visible slice of the $1.5B DHS C-UAS program and Body Mini converting trials into Fortune 500 ACV
- Axon 911 wins 200+ emergency dispatch contracts by end of 2027, creating the only end-to-end public safety platform from 911 call through court submission and re-rating the addressable market
- Revenue trajectory toward $5.5B+ in 2027 forces consensus upgrades, supporting ~15× NTM revenue and a re-rating toward the prior ATH zone near $850–900

---

InvestMoat is an open-source research and education framework. Nothing here is financial advice. Past performance does not guarantee future results.